Microglia are the resident immune cells of the central nervous system (CNS). They are derived from the embryonic hematopoiesis and populate the CNS during neuroectodermal development (Ginhoux et al. 2010) . Later in embryonic development, the ionized calcium-binding adaptor molecule-1 (Iba1/Aif1)-positive microglial precursors proliferate locally within the CNS to become adult microglia (Chan et al. 2007) . They act as local regulators of CNS development and neuronal survival via release of cytokines, chemokines and growth factors and the silent phagocytosis of apoptotic material. Their ability to clear apoptotic material without inflammation is important for brain tissue homeostasis and repair. But microglia can also recognize and phagocytose invading bacteria and can release reactive oxygen species, thus being part of the active immune defense. In the healthy brain, microglia continuously scan the brain parenchyma with highly branched and motile processes in order to recognize any alterations occurring in the brain. Upon injury or inflammatory stimuli, microglia become activated, migrate to the site of damage and act as immune cells and phagocytes. In response to injury or inflammation microglia change from an immunological silent to an activated state. The effects of activated microglia can be highly divers ranging from neurotoxic to neuroprotective ones. Thus, microglia are a flexible cell type that sense the microenvironment, particularly the glycocalyx of cells or the capsule of microbes. To respond appropriate to the processes in the brain, microglia express a whole set of recognition receptors.
Microglial immunoreceptor tyrosine-based activation motif-signaling receptors and their involvement in development and neurodegenerative diseases
Recognition receptors with an immunoreceptor tyrosine-based activation motif (ITAM) play an important role in phagocytosis of pathogens, cellular debris and apoptotic material. Several receptors are expressed on the microglia that signal via ITAM to induce phagocytosis. Phagocytosis of degenerated cellular material or microbes is a highly conserved process from worms to mammals. Draper is a major phagocytic receptor of the fruit fly with an ITAM in the intracellular domain (Ziegenfuss et al. 2008) . Glial cell-mediated clearance of apoptotic cells in the CNS of the fruit fly involves a Draper-ITAM-syk-signaling cascade (Ziegenfuss et al. 2008) , which is very similar to the immunoreceptor-ITAM-syk-signaling pathway of mammals. Upon ligand binding in mammals, activatory receptors associate with an ITAM-containing adaptor protein such as TYROBP/ DAP12 (Figure 1) . Then, the ITAMs become phosphorylated by members of the Src kinase family and via a number of downstreamsignaling cascades, the activated cell starts to migrate and phagocytose. One of the receptors that signals via TYROBP/DAP12 is the complement receptor 3 (CD11b/CD18), a microglial receptor involved in the recognition of complement-opsonized material (Figure 1 ). The classical complement cascade and the complement receptor 3 are also involved in synaptic pruning during development (Stevens et al. 2007; Schafer et al. 2012) . Different components of the synapse can be targets of microglial processes that are scanning their environment (Tremblay et al. 2010) . During development, microglia have been shown to engulf and eliminate synapses (Paolicelli et al. 2011) leading to the fine-tuning of neural circuits. Removal of neurites by the complement system can be recapitulated in vitro by removing the sialic acid residues from the neuronal glycocalyx. Such a desialylated glycocalyx of neurons can be opsonized by C1q and removed in a complement receptor 3-dependent manner by co-cultured microglia (Linnartz et al. 2012) . Another TYROBP/DAP12-signaling molecule is the triggering receptor expressed on myeloid cells 2 (TREM2; Figure 1 ) that can be shed from the cell surface to act as possible decoy receptor (Wunderlich et al. 2013 ). Variants of this TREM2 receptor have now been connected to the risk of developing Alzheimer's disease (AD) (Guerreiro et al. 2012; Jonsson et al. 2013) , frontotemporal dementia (Rayaprolu et al. 2013; Borroni et al. 2014 ) and Parkinson's disease (Rayaprolu et al. 2013) . The activatory ITAM signaling is not only the trigger for phagocytosis but also for nicotinamide adenine dinucleotide phosphate oxidase-mediated release of reactive oxygen species, intermediates that are highly neurotoxic. Interestingly, this DAP12/ TYROBP-ITAM-mediated radical production was closely linked to late onset AD by an integrative network-based approach (Zhang et al. 2013 ). Thus, ITAM-signaling and ITAM-signaling receptors seem to be involved in developmental and neurodegenerative processes.
Inhibitory Siglecs interfere with microglial ITAM signaling
Activation of microglial cells by ITAM-signaling receptors is counter regulated by receptors-containing immunoreceptor tyrosine-based inhibition motifs (ITIMs; Figure 1 ) . Most CD33-related Siglecs, a subgroup of the immunoglobulin (Ig) superfamily that recognizes sialic acid residues of glycoproteins and glycolipids, have one or more ITIMs in the cytoplasmic domain (Crocker 2005; Crocker et al. 2007 ). Inhibitory signaling via ITIMs counteracts the activatory signal by the recruitment of SH2 domain-containing tyrosine phosphatases, mainly Src homology region 2 domaincontaining phosphatase-1 (SHP1; tyrosine-protein phosphatase non-receptor type 6, PTPN6) (Crocker et al. 2007 ). Thus, intermediates of the ITAM-signaling cascade are dephosphorylated leading to an inactivation of the cell.
Recent data suggest that ITIM receptors might also inhibit inflammasome activation via inactivation of ITAM-mediated Fig. 1 . ITAM-and ITIM-signaling cascades in microglia counterbalance reactive oxygen species production and inflammasome activation. Inhibitory receptors such as most Siglecs recruit SHP1/2, which can in turn terminate intracellular signals emanating from ITAM signaling receptors via their phosphatase activity. The ITIM signaling inhibits Syk activation and thus prevents production of reactive oxygen species by microglia. The principal Toll-like receptor signal transduction pathway can trigger on the one hand the activation of the NF-κB pathway leading to the production of pro-inflammatory cytokines. On the other hand, it also leads to the activation of JNK pathways. Stimulation of Syk-and JNK-dependent pathways is required for inflammasome activation. The exact kinase ("X") that catalyzes the phosphorylation for inflammasome activation after stimulation via Syk-and JNK pathways remains unknown. Thus, ITIM signaling via inhibition of Syk prevents inflammasome activation (Futosi et al. 2013; Hara et al. 2013; Linnartz and Neumann 2013; Neumann and Ruland 2013) . CR3, complement receptor 3; IL, interleukin; ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-based inhibition motif; JNK, Jun N-terminal kinase; NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3, nucleotide-binding oligomerization domain-leucine-rich repeats containing pyrin domain 3; P, phosphate; SHP1/2, Src homology region 2 domain-containing phosphatase-1/2; Siglecs, sialic acid-binding immunoglobulin type lectins; Syk, spleen tyrosine kinase; TIR, Toll/interleukin-1 receptor; TREM2, triggering receptor expressed on myeloid cells 2.
Siglec of microglia
Syk signaling (Hara et al. 2013) (Figure 1 ). It was shown that both, Syk kinase and JNK kinase signaling, are required to activate the NLRP3 inflammasome (Hara et al. 2013; Neumann and Ruland 2013) . While JNK is activated via TAK1 of toll-like receptor (TLR) stimulation, Syk kinase is stimulated by receptors signaling via an ITAM (Figure 1) .
Recently, we have demonstrated that the ectopic expression of the human microglial gene Siglec-11 in mouse microglia downregulates their pro-inflammatory cytokine gene transcription and their phagocytic capacity (Wang and Neumann 2010) , confirming that the ITIM signaling is an opponent of the phagocytosis-associated ITAM-Syk-signaling pathway. Another good example for this is the well-characterized human CD33-related Siglec-5. It was reported that phagocytosis of apoptotic bodies by macrophages was inhibited by sialooligosaccharide ligands of Siglec-5 and monoclonal antibodies to Siglec-5 (Rapoport et al. 2005) . More recently, a study showed that binding of some Group B Streptococcus to Siglec-5 functions to impair human leukocyte phagocytosis and oxidative burst and promotes bacterial survival (Carlin et al. 2009 ). Moreover, the ITIM signaling of mouse Siglec-E has been shown to inhibit the phagocytosis of neural debris and the associated production of reactive oxygen species by microglial cells ).
Involvement of SHP1 and SHP2 as second messenger of inhibitory Siglec signaling in microglial immunosuppression
The phosphatases SHP1 or SHP2 are molecules often involved in the inhibitory-signaling cascade of Siglecs. Several studies showed that Siglecs interact with SHP1 and SHP2. Thus, it has been shown that SHP1 physically interacts with Siglec-9 (Rashmi et al. 2009 ) and Siglec-10 ( Kitzig et al. 2002) , and SHP2 associates with Siglec-G (Chen et al. 2013 ). SHP1 as well as SHP2 bound to phosphorylated Siglec-3 (Walter et al. 2008) and Siglec-11 (Angata et al. 2002) . SHP1 knockout mice are premature lethal at 10-12 weeks of age (Pao et al. 2007 ). Therefore, most data on the role of SHP1 for brain function have been obtained from mutant allelic viable variant, hypomorphic motheaten (me V /me V ) mice with a spontaneous mutation leading to reduced levels of the SHP1. Thus, a reduced level of SHP1 is consequently leading to a reduced signal emerging from a diversity of proteins that can activate SHP1 such as inhibitory Siglec receptors. The mutant hypomorphic motheaten mice showed a decreased number of glial cells in the CNS (Wishcamper et al. 2001) . Moreover, microglial cells were isolated from these mice and analyzed in vitro. Lipopolysaccharide (LPS)-activated SHP1-mutant motheaten microglia released increased levels of nitric oxide, tumor necrosis factor-α and interleukin-1 β (IL-1β) (Zhao et al. 2006) . Furthermore, the cytokine profile was altered in the mouse hindbrain of the SHP1-mutant motheaten mice with increased levels of pro-inflammatory cytokines (Zhao and Lurie 2004) . Microglial changes have not only been observed in the CNS, but deficiency of SHP1 protein-tyrosine phosphatase in "viable motheaten" mice resulted also in retinal degeneration (Lyons et al. 2006) . Thus, data indicate that SHP1 signaling is necessary for brain homeostasis to keep microglia in a silent state.
Conserved Siglec on microglia
Sialoadhesin (Siglec-1, CD169) Sialoadhesin is thought to have adhesive function since it neither has a cytosolic ITIM nor a positive charged residue to bind ITAM-containing adaptor proteins. Moreover, due to the large numbers of 17 Ig domains that extend the binding site away from the membrane sialoadhesin is thought to be important for adhesion (Crocker et al. 1994) . Sialoadhesin was shown to be involved in cell-cell and cell-pathogen recognition (Bradford et al. 2012) . It binds to sialic acids of O-and N-linked oligosaccharides and of glycolipids. Sialoadhesin is expressed on macrophage subtypes occupying secondary lymphoid tissue (reviewed in O'Neill et al. 2013 ). Its expression is restricted to members of the mononuclear phagocytic lineage. However, the expression of sialoadhesin on microglia is still discussed as only few studies have demonstrated the expression of sialoadhesin on activated microglia. The expression seems to be dependent on the exposure to plasma proteins. Thus, in the brain parenchyma expression of sialoadhesin on microglia was only detected 7 days after traumatic injury and the breakdown of the blood-brain barrier (Perry et al. 1992) . But, the origin of these sialoadhesin-positive microglia is unclear and it is unknown whether they were activated resident microglia or recruited, blood-derived cells (Perry et al. 1992 ). Moreover, during retinal degeneration, microglia became activated and expressed sialoadhesin (Hughes et al. 2003) . However, the function of sialoadhesin expression on microglia is still unknown.
CD33-related Siglecs on microglia
Mouse Siglec-E Siglec-E is a mouse CD33-related Siglec that binds to a wide range of sialyloligosaccharides, but always with a preference for the sialic acid form Neu5Ac (Redelinghuys et al. 2011) . In respect to sequence homology, Siglec-E is most similar to human Siglec-7, -8 and -9, but from these three human Siglecs only Siglec-7 and -9 have a similar expression profile. Siglec-E contains an ITIM and an ITIM-like domain in its cytoplasmic tail (Figure 1 ). Siglec-E was recently detected on microglia (Gautier et al. 2012; Claude et al. 2013 ) and has been shown to be involved in neuroprotection. As mentioned before, Siglec-E inhibited the phagocytosis of neural debris and prevented the production of superoxide radicals induced by challenge with neural debris. Moreover, a neuroprotective effect of microglial Siglec-E was demonstrated in co-culture of mouse microglia and neurons that was dependent on neuronal sialic acid residues. After knockdown of microglial Siglec-E, an increased neurotoxicity of microglia mediated via reactive oxygen species was observed. Data suggested that Siglec-E recognizes the intact neuronal glycocalyx and has neuroprotective function by preventing phagocytosis and the associated oxidative burst .
Mouse Siglec-H Expression of Siglec-H has been observed on plasmacytoid dendritic cells (Zhang et al. 2006 ) and on interferon-γ activated or M1-subtype microglia (Kopatz et al. 2013 ). Furthermore, Siglec-H has no ITIM in its cytoplasmic region, but carries a charged lysine residue in the transmembrane region. Due to this residue Siglec-H can associate and signal via the adaptor B Linnartz-Gerlach et al. protein DAP12/TYROBP (Figure 1 ). As mentioned above, DAP12/TYROBP has an ITAM in its cytoplasmic tail and might lead to a signal that is contrary to the signal evolved by most other Siglecs displaying an ITIM. However, in contrast to the observation that Siglec-H associates with DAP12/TYROBP it has been shown that activation of Siglec-H by a monoclonal antibody inhibits interferon-α secretion (Blasius et al. 2006) . The authors suggest that low-level activation of DAP12/TYROBP only leads to a partial activation sufficient to recruit activatingsignaling mediators, but insufficient to mediate downstream signaling. Moreover, Siglec-H deficiency induced higher interferon-α levels (Takagi et al. 2011; Puttur et al. 2013 ). The results indicate that Siglec-H provides an inhibitory signal for TLR9-mediated downstream cascades to stop the cytokine production (Takagi et al. 2011) . Siglec-H contains all structural features necessary for sialic acid recognition. However, no binding to common sialoglycoconjugates has been observed so far (Zhang et al. 2006) . Thus, the ligand and the function of Siglec-H remained elusive. Recently, it has been shown that Siglec-H can bind to mouse glioma lines, but not to astrocytes or other normal mouse cells (Kopatz et al. 2013) . Microglial cells stimulated to express Siglec-H engulfed intact glioma cells without prior induction of apoptosis dependent on Siglec-H and its adapter molecule DAP12/TYROBP (Kopatz et al. 2013 ). Thus, Siglec-H might recognize an altered glycocalyx structure on glioma cells and might be a clearance system for single neoplastic transformed cells.
Human and mouse Siglec-3 (CD33)
Siglec-3 is a transmembrane receptor expressed on the surface of cells from the myeloid lineage (Garnache-Ottou et al. 2005) . Recently, three studies came up in parallel with a Siglec-3 polymorphism as candidate gene for the increasing risk to develop late onset AD Hollingworth et al. 2011; Naj et al. 2011) . It is unclear how Siglec-3 is linked to AD from a mechanistic point of view. However, one could speculate that microglia as a prototypic immature macrophage cell type might express Siglec-3 and that the AD-linked polymorphism is leading to microglial dysfunction. This hypothesis is underlined by the results of Griciuc et al. demonstrating a higher expression of Siglec-3 in AD samples and a co-localization of Siglec-3 with a microglial marker. Normalizing the Siglec-3 levels to the microglial marker demonstrated that the increased expression is not due to a higher number of microglia (Griciuc et al. 2013) . Moreover, the numbers of Siglec-3-positive microglia were increased in frontal cortices of AD patients compared with agematched controls and enriched around amyloid plaques (Griciuc et al. 2013) . A positive correlation was found between amyloid plaque burden and the numbers of Siglec-3-positive microglia in AD cases (Griciuc et al. 2013) . However, the function of Siglec-3 in humans is still unclear. In the mouse system, Siglec-3 seems to be involved in the amyloid-β plaque burden. Murine primary microglia deficient for Siglec-3 showed a strong increase in amyloid β42 internalization compared with wild-type primary microglia (Griciuc et al. 2013) . But one major challenge is the diversity of human and mouse Siglec-3. Although both molecules share some sequence homology they are quite diverse in signaling and ligand recognition. While the transmembrane portion of mouse Siglec-3 has a charged residue hinting towards an association with an ITAM adaptor protein, the intracellular portion of human Siglec-3 contains one ITIM that recruits the phosphatase SHP1 and an ITIM-like motif both leading to inhibition of distinct cellular activities (Varki and Angata 2006) (Figure 1) . Activation of Siglec-3 might lead to opposite effects in cells of the mouse or human system. Thus, results obtained in the mouse cannot be directly translated into the human system.
Human Siglec-11 Siglec-11 was first identified in 2002 and characterized as a primate-lineage-specific gene with a human-lineage-specific expression pattern (Hayakawa et al. 2005) . In humans, Siglec-11 was widely expressed on tissue macrophages, including microglia in the brain (Hayakawa et al. 2005) . The non-human primates showed no expression of Siglec-11 in the brain. Despite the fact that it shares 90% gene sequence homology to the extracellular domains of Siglec-10, which binds to both α2.3-and α2.6-linked sialic acids, Siglec-11 selectively binds to α2.8-linked sialic acid trimers. Like other inhibitory Siglecs, Siglec-11 has ITIM motifs in the cytosolic tail.
Although not much is known about the function of Siglec-11 on microglia, light has been shed on Siglec-11 as a negative regulator of microglia, not only on inflammatory but also on phagocytosis function. In our study, gene transcription and protein expression of Siglec-11 were confirmed in human brain tissue samples on microglia (Wang and Neumann 2010) . In vitro experiments further showed that in murine microglial cells ectopically expressing human Siglec-11, stimulation of Siglec-11 by cross-linking suppressed the LPS induced gene transcription of the pro-inflammatory mediators IL-1β and nitric oxide synthase-2. Furthermore, phagocytosis of apoptotic neuronal material was reduced in Siglec-11 expressing microglia. Co-culture of Siglec-11 expressing microglia and neurons demonstrated neuroprotective functions of Siglec-11 (Wang and Neumann 2010) . This neuroprotective effect of Siglec-11 was diminished by sialidase (EndoN) treatment of neurons that led to the removal of α2.8-linked sialic acids from the cell surface. However, the effect was not affected by an EndoN-treatment of microglia, indicating that Siglec-11 might function through the binding of α2.8-linked sialic acids on neurons. For the binding of carbohydrate receptors to their ligands, a model system of multimerization has been suggested. Normally, binding to a carbohydrate is a low-affinity binding that is not leading to biological signaling. Therefore, it is necessary that several receptors pair together in a way that the ligand is recognized by a cluster of receptors . This multivalency seems to be essential for protein-carbohydrate interactions and responses in a cellular system Cohen and Varki 2014) . Thus, only a defined level of multivalency in this interaction either due to the glycan density or the number of glycan epitopes leads to a biological effect (Dam and Brewer 2010; Cohen and Varki 2014) .
Human Siglec-16 Siglec-16 was first reported as a pseudogene. However, further studies clarified that in some humans it does encode a functional protein with potential activatory properties. It is a TYROBP/ DAP12-associated receptor (Figure 1 ) with proposed expression on microglia or macrophages of the CNS (Cao et al. 2008) . Siglec-16 shares over 99% of sequence identity at the Siglec of microglia first two Ig-like domains to that of Siglec-11 and is proposed to be a "paired" Siglec to Siglec-11 for balancing the functions of microglia. No functional data on Siglec-16 are available so far. Yet, it is likely that Siglec-16 might share significant sialic acid binding specificity with Siglec-11 and it is reasonable to assume that Siglec-16 might function as an opposite receptor to Siglec-11. Since only some people of the human population might have this activatory Siglec-16 expressed on brain microglia, it is particular interesting to investigate whether it is involved in modulating microglial function and the interaction between microglia and neurons.
Conclusion
Microglia are the resident innate immune cells of the CNS. They can mediate either neurotoxic or neuroprotective events. Microglia continuously sense the cellular glycosylation composition in order to reflect the physical condition of the target cell. They can respond to an intact or altered glycocalyx in an appropriate way. Microglial inhibitory Siglecs sense the sialic acid cap that exists on the intact glycocalyx leading to a protective phenotype of the microglial cells. Interactions between microglial Siglecs and the neuronal sialic acid residues prevent phagocytosis and the associated oxidative burst during tissue remodeling and disease processes. Thus, new therapeutic strategies can be suggested utilizing the knowledge of protective Siglec receptors on microglia. By using substances that stimulate microglial Siglecs, a specific phenotype can be created that contributes to a neuroprotective and repair promoting microenvironment.
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